Article Information
History
- March 16, 2022.
Article Versions
- Version 1 (March 9, 2022 - 12:18).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Subhash Thuluva1,*,
- Vikram Paradkar1,
- Kishore Turaga1,
- SubbaReddy Gunneri1,
- Vijay Yerroju1,
- Rammohan Mogulla1,
- Mahesh Kyasani1,
- Senthil Kumar Manoharan1,
- Guruprasad Medigeshi2,
- Janmejay Singh2,
- Heena Shaman2,
- Chandramani Singh3 and
- A Venkateshwar Rao4
- 1Biological E Limited, 18/1&3, Azamabad, Hyderabad – 500 020, Telangana, India
- 2Vaccine and Infectious Disease Research Center, Translational Health Science and Technology Institute, Faridabad 121001, India
- 3Department of Community and Family Medicine, All India Institute of Medical Sciences, Patna, Bihar, India
- 4Department of General Medicine, St. Theresa’s Hospital, Hyderabad, India
- ↵*Corresponding Author Name: Subhash Thuluva, Biological E Limited, 18/1&3, Azamabad, Hyderabad – 500 020, Telangana, India, Phone: +91 40 7121 6248. mail: subhash.thuluva{at}biologicale.com
Posted March 16, 2022.
Selection of optimum formulation of RBD-based protein sub-unit covid19 vaccine (Corbevax) based on safety and immunogenicity in an open-label, randomized Phase-1 and 2 clinical studies
